SKI‑II reverses the chemoresistance of SGC7901/DDP gastric cancer cells

Liu,Ying; Zhu,Zuan; Cai,Hongxing; Liu,Qinghua; Zhou,Honglian; Zhu,Zhengqiu

doi:10.3892/ol.2014.2083

SKI‑II reverses the chemoresistance of SGC7901/DDP gastric cancer cells

Authors:
- Ying Liu
- Zuan Zhu
- Hongxing Cai
- Qinghua Liu
- Honglian Zhou
- Zhengqiu Zhu
View Affiliations

Affiliations: Department of Pathology, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China, Department of Gastroenterology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China, Department of Forensic Medicine, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China, Department of Medical Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China
Published online on: April 25, 2014 https://doi.org/10.3892/ol.2014.2083
Pages: 367-373

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin is frequently used in treating gastric cancers; however, acquired resistance to the drug often reduces the efficacy of therapy. The present study analyzed the efficacy of the combination of 4‑[4‑(4‑chloro‑phenyl)‑thiazol‑2‑ylamino]-phenol (SKI‑Ⅱ) and cisplatin [cis‑diamminedichloroplatinum (II); DDP] on the gastric cancer SGC7901/DDP cell line. The results revealed that SKI‑Ⅱ and DDP had a clear synergistic effect. Glutathione (GSH) and glutathione S‑transferase (GST) levels decreased significantly subsequent to the cells being treated with the combination of DDP and SKI‑Ⅱ compared with the cells that were treated with DDP or SKI‑Ⅱ alone. Phosphorylated extracellular-signal-regulated kinase (p‑ERK) and phosphorylated c-Jun N-terminal kinase (p‑JNK) expression levels also decreased following treatment with SKI‑Ⅱ. The results suggested that SKI‑Ⅱ is able to reverse the drug resistance in human gastric carcinoma cells and enhance the antitumor effect of DDP through the ras/mitogen‑activated protein kinase (MAPK) proliferation pathway.

View Figures

View References

1	Lekakis L, Tryfonopoulos D, Pistamatzian N, et al: Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases. Anticancer Res. 32:1833–1837. 2012.
2	García-Velasco A, Durán I, García E, et al: Biological markers of cisplatin resistance in advanced testicular germ cell tumours. Clin Transl Oncol. 14:452–457. 2012.
3	Yanagawa M, Tatsumi M, Miyata H, et al: Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med. 53:872–880. 2012.
4	Kumar A and Saba JD: Lyase to live by: sphingosine phosphate lyase as a therapeutic target. Expert Opin Ther Targets. 13:1013–1025. 2009.
5	Hla T: Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol. 15:513–520. 2004.
6	Ogretmen B and Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 4:604–616. 2004.
7	Spiegel S and Milstien S: Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem. 277:25851–25854. 2002.
8	Taha TA, Argraves KM and Obeid LM: Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy. Biochim Biophys Acta. 1682:48–55. 2004.
9	Kumar A, Wessels D, Daniels KJ, et al: Sphingosine-1-phosphate plays a role in the suppression of lateral pseudopod formation during Dictyostelium discoideum cell migration and chemotaxis. Cell Motil Cytoskeleton. 59:227–241. 2004.
10	Oskouian B and Saba JD: Death and taxis: what non-mammalian models tell us about sphingosine-1-phosphate. Semin Cell Dev Biol. 15:529–540. 2004.
11	Spiegel S, English D and Milstien S: Sphingosine 1-phosphate signaling: providing cells with a sense of direction. Trends Cell Biol. 12:236–242. 2002.
12	French KJ, Upson JJ, Keller SN, et al: Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 318:596–603. 2006.
13	Roukos DH and Kappas AM: Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol. 2:98–107. 2005.
14	Menges M, Schmidt C, Lindemann W, et al: Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate. J Cancer Res Clin Oncol. 129:423–429. 2003.
15	Zhao Z, Wang J, Tang J, et al: JNK-and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem J. 444:291–301. 2012.
16	Hasegawa M, Ishiguro K, Ando T and Goto H: Geranylgeranylacetone attenuates cisplatin-induced reductions in cell viability by suppressing the elevation of intracellular p53 content without heat shock protein induction. Nagoya J Med Sci. 74:123–131. 2012.
17	Vasconcelos FC, Cavalcanti GB Jr, Silva KL, et al: Constrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res. 31:445–454. 2007.
18	Patel NH and Rothenberg ML: Multidrug resistance in cancer chemotherapy. Invest New Drugs. 12:1–13. 1994.
19	Legrand O, Simonin G, Beauchamp-Nicoud A, et al: Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood. 94:1046–1056. 1999.
20	Valko M, Rhodes CJ, Moncol J, et al: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 160:1–40. 2006.
21	Cobb MH and Goldsmith EJ: How MAP kinases are regulated. J Biol Chem. 270:14843–14846. 1995.
22	Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009.
23	Lee HG, Minematsu H, Kim KO, et al: Actin and ERK1/2-CEBPβ signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells. Biomaterials. 32:9197–9206. 2011.
24	McGlynn LM, Kirkegaard T, Edwards J, et al: Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res. 15:1487–1495. 2009.
25	Atmaca A, Pauligk C, Steinmetz K, et al: Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer. Oncology. 80:130–134. 2011.
26	Wasserman WW and Fahl WE: Functional antioxidant responsive elements. Proc Natl Acad Sci USA. 94:5361–5366. 1997.
27	Li Y and Jaiswal AK: Regulation of human NAD(P)H: quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element. J Biol Chem. 267:15097–15104. 1992.
28	Rushmore TH and Pickett CB: Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. J Biol Chem. 265:14648–14653. 1990.
29	Prestera T, Holtzclaw WD, Zhang Y and Talalay P: Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci USA. 90:2965–2969. 1993.